A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes

Cancer Informatics

Volumn 9, Issue , 2010, Pages 93-103

  Li, Lang ^a   Borges, Silvana ^a   Jason, Robarge D ^a   Shen, Changyu ^a   Desta, Zeruesenay ^a   Flockhart, David ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Genotype Phenotype association; Mixture model; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN; CYTOCHROME P450 2B6; EFAVIRENZ; ENDOXIFEN; NORTAMOXIFEN;

ALGORITHM; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PROTEIN EXPRESSION; ALLELE; GENETIC ALGORITHM; GENOTYPE; LIVER TISSUE; PHENOTYPE; SIMULATION;

EID: 77952899736     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/cin.s3493     Document Type: Article

References (25)

1. Walgren RA, Meucci MA, McLeod HL. Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up? Journal of Clinical Oncology. 2005;23:7342-9.
2. Christensen R. Plane Answers to Complex Questions, The Theory of Linear Models. New York: Springer-Verlag. 1987.
3. Toothaker EL. Multiple Comparison Procedures. New York: Wiley. 1993.
4. Culver house. 2003.
5. Pearson KP. Contributions to the mathematical theory of evolution. Philosophical Transactions A. 1895;186:342-414.
6. Schork NJ, Allison DB, Thiel B. Mixture distributions in human genetics research. Statistical Methods in Medical Research. 1996;5:155-78.
7. McLachlan G, Peel D. Finite Mixture Model. New York: Wiley. 2000.
8. Seidel W, Mosler K, Alker M. A cautionary note on likelihood ratio tests in mixture models. Annals of the Insititute of Statistical Mathematics. In press. 2000.
9. Ghosh JK, Sen PK. On the asymptotics performance of the log-likelihood ratio statistics for the mixture model and related results. Proceedings of the Berkeley Conference in Honor of J. Neyman and J Kiefer. 1985;2: 799-806.
10. Hartigan JA. A failure of likelihood asymptotics for noraml mixture. Proceedings of the Berkeley Conference in Honor of J. Neyman and J Kiefer. 1985;2:807-10.
11. Chen J, Kalbfleisch JD. A modified likelihood ratio test for homogeneity in finite mixture models. Journal of Royal Statistical Society, Series B. 2001;63:19-29.
12. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenetics. 2007;8: 547-58.
13. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11(5):399-415.
14. Culverhouse R, Klein T, Shannon W. Detecting Epistatic Interactions Contributing to Quantitative Traits. Genetic Epidemiology. 2004;27: 141-52.
15. Dahl M, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther.1992;12-7.
16. Sachse CBJ, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Human Genetics. 1997;60:284-95.
17. Zanger U, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Arch Pharmacol. 2004;369:23-37.
18. Dahl M, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. J Pharmacol Exp Ther. 1995;274:516-20.
19. Lundqvist E, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226:327-38.
20. Zukunft J, Lang T, Richter T, et al. A natural CYP2B6 TATA box polymorphism (-82T-> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol. 2005;67(5):1772-82.
21. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids. 2004;18:2391-400.
22. Tsuchiya KH, Gatanaga H, Tachikwa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-6.
23. Lang T, Klein K, Richter T, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther. 2004;311:34-43.
24. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005;15:861-73.
25. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13:619-26.